Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Dynavax ( (DVAX) ) just unveiled an update.
On February 10, 2025, Dynavax Technologies Corporation entered into a new Supply Agreement with West Pharmaceutical Services, Inc. for the manufacture and supply of syringe stoppers for its HEPLISAV-B® vaccine, replacing a prior agreement from 2016. This new agreement, effective for four years with possible extensions, outlines volume-based pricing subject to changes according to a specified price index and includes provisions for termination due to breach or insolvency. Additionally, on February 13, 2025, the company’s Board of Directors appointed Kelly MacDonald as the principal accounting officer, expanding her responsibilities as the Chief Financial Officer.
More about Dynavax
Dynavax Technologies Corporation operates in the biotechnology industry, focusing on the development and commercialization of novel vaccines. One of its primary products is the HEPLISAV-B® vaccine, which is aimed at preventing hepatitis B infection.
YTD Price Performance: -1.63%
Average Trading Volume: 1,767,180
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.67B
For detailed information about DVAX stock, go to TipRanks’ Stock Analysis page.
